Recent Analysts’ Ratings Changes for United Therapeutics (UTHR)

Several brokerages have updated their recommendations and price targets on shares of United Therapeutics (NASDAQ: UTHR) in the last few weeks:

• 8/13/2026 – United Therapeutics was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 8/6/2026 – United Therapeutics was given a new $515.00 price target by Morgan Stanley.
• 8/6/2026 – United Therapeutics had its price target lowered by Royal Bank Of Canada from $704.00 to $677.00. They now have an “outperform” rating on the stock.
• 7/31/2026 – United Therapeutics was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 7/23/2026 – United Therapeutics had its price target raised by JPMorgan Chase & Co. from $685.00 to $687.00. They now have an “overweight” rating on the stock.
• 7/10/2026 – United Therapeutics had its price target lowered by Bank of America Corporation from $620.00 to $613.00. They now have a “neutral” rating on the stock.
• 7/7/2026 – United Therapeutics had its price target raised by Royal Bank Of Canada from $701.00 to $704.00. They now have an “outperform” rating on the stock.

Insider Activity

In other news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $517.05, for a total value of $4,291,515.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $23,356,182.60. The trade was a 15.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $515.03, for a total transaction of $4,892,785.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $167,097,878.29. This trade represents a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 443,075 shares of company stock valued at $241,508,744 in the last ninety days. 8.60% of the stock is currently owned by company insiders.

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.